Widely spread sexually-transmitted diseases like genital herpes, caused predominantly by the infection with Herpes simplex virus (HSV) type 2, and human papilloma virus (HPV) infections pose considerable threat to global health.There is no efficient HSV vaccine developed yet; acyclovir derivates inhibit HSV replication to some level, however, the drug-resistant mutants of HSV and the dosage problems may develop with time.High-risk types of HPV occasionally lead to genital and anal squamous cell cancers.There is no efficient antiviral against HPV developed yet, existing vaccine may only protect women from infection.New nanosize anti HSV and HPV drugs of natural origin were tested in vitro for the inhibition of viral replication in permissive cell cultures, including organotypic cell cultures.The results show inhibition of viral replication for up to 85% when very low concentration of antiviral nanoparticles were used.Even high concentrations of antivirals were nontoxic in cultures.In acyclovir control the inhibition of replication never exceeded 70%, as compared to control.In HSV+HPV experiments preincubation or coincubation with low concentration of antivirals inhibited viral replication for up to 80%.